Dose Escalation and Efficacy Trial of GVAX® Prostate Cancer Vaccine

Cell Genesys80 enrolled

Overview

The purpose of this study is to evaluate clinical and laboratory safety in patients receiving 4 different doses of GVAX® Prostate Cancer Vaccine in order to determine a maximum tolerated dose.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Prostate Cancer

Interventions

Immunotherapy allogeneic GM-CSF secreting cellular vaccineBIOLOGICAL

Eligibility

Sex: MALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of adenocarcinoma of the prostate * Metastatic prostate cancer deemed to be unresponsive or refractory to hormone therapy * Detectable metastases * ECOG performance status of 0 or 1 Exclusion Criteria: * Transitional cell, small cell, neuroendocrine, or squamous cell prostate cancer * Significant cancer related pain * Prior gene therapy, chemotherapy, or immunotherapy

Locations (12)

South Orange County Medical Research Center

Laguna Woods, California, United States

UCSF

San Francisco, California, United States

West Coast Clinical Research

Tarzana, California, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.